Baseline demographic and disease-related characteristics of patients (N = 46)
| Characteristic . | Value . |
|---|---|
| Sex, N | |
| Male | 32 |
| Female | 14 |
| Median age, y (IQR) | 56 (50-62) |
| ECOG, N (%) | |
| 0 | 23 (51) |
| 1 | 18 (40) |
| 2 | 4 (9) |
| Isotype, n (%) | |
| Immunoglobulin G | 31 (67.5) |
| Immunoglobulin A | 8 (17.5) |
| Light chain | 5 (11) |
| Other | 2 (4) |
| ISS stage, N (%) | |
| I | 21 (46) |
| II | 22 (48) |
| III | 3 (6) |
| Median bone marrow plasma cells, % (IQR) | 19.5 (12.0-30.5) |
| Median creatinine, µmol/L (IQR) | 80 (65-91) |
| Median calcium, mmol/L (IQR) | 2.28 (2.21-2.39) |
| Median β2-microglobulin, mg/L (IQR) | 2.85 (2.12–3.47) |
| Median albumin, g/L (IQR) | 35.6 (31.8-41.6) |
| FISH analysis, N (%) | 43 evaluable/46 |
| del(17p) with a 50% positive cutoff, | 4 (9.5) |
| t (4;14), | 5 (11.5) |
| Characteristic . | Value . |
|---|---|
| Sex, N | |
| Male | 32 |
| Female | 14 |
| Median age, y (IQR) | 56 (50-62) |
| ECOG, N (%) | |
| 0 | 23 (51) |
| 1 | 18 (40) |
| 2 | 4 (9) |
| Isotype, n (%) | |
| Immunoglobulin G | 31 (67.5) |
| Immunoglobulin A | 8 (17.5) |
| Light chain | 5 (11) |
| Other | 2 (4) |
| ISS stage, N (%) | |
| I | 21 (46) |
| II | 22 (48) |
| III | 3 (6) |
| Median bone marrow plasma cells, % (IQR) | 19.5 (12.0-30.5) |
| Median creatinine, µmol/L (IQR) | 80 (65-91) |
| Median calcium, mmol/L (IQR) | 2.28 (2.21-2.39) |
| Median β2-microglobulin, mg/L (IQR) | 2.85 (2.12–3.47) |
| Median albumin, g/L (IQR) | 35.6 (31.8-41.6) |
| FISH analysis, N (%) | 43 evaluable/46 |
| del(17p) with a 50% positive cutoff, | 4 (9.5) |
| t (4;14), | 5 (11.5) |
ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; ISS, International Staging System.